A Dose-ranging Study of Fluticasone Furoate (FF)
Completed · Phase 2 · Has a placebo group
Conditions studied: Asthma
In brief
This is a Phase IIb, multi-centre, stratified, randomised, double-blind, double-dummy, parallel-group, placebo and active controlled study in children aged 5-11 years with persistent uncontrolled asthma. Subjects meeting all of the inclusion criteria and none of the exclusion criteria at the screening visit (Visit 1) will enter a four week run-in period during which time they will continue their current medications. Visit 2 will occur two weeks into the run-in period to allow a review of compliance with daily diary and run-in medication. At Visit 3 (end of run-in/randomization visit), subjects meeting the eligibility criteria who remain uncontrolled despite baseline therapy will be stratified based on pre screening inhaled corticosteroid (ICS) use. Once stratified, subjects will be randomised to the treatment phase of the study where they will receive one of five treatments for 12 weeks. Approx 1200 subjects ages 5 to 11 will be screened to achieve 575 randomized for a total of 115 randomized/evaluable subjects per treatment arm. Subjects will attend on-treatment visits at 2, 4, 8 and 12 weeks (Visits 4, 5, 6 and 7 respectively). A follow-up contact will be performed one week after completing study medication. All subjects must attempt spirometry measurements at Visits 1 and 3. For all subjects, a timed 24-hour urine collection for urinary cortisol and creatinine excretion will be performed prior to randomization at Visit 2 and within 7 days prior to Visit 7. All subjects must perform PEF daily between visits 1 and 7. The primary endpoint will be change from baseline in pre-dose (i.e. dosing trough) PM PEF from patient hand held electronic daily diary at Endpoint (Endpoint is defined as the mean over the last 7 days of treatment). Safety assessments include adverse events, oropharyngeal examinations, clinical chemistry, urinary cortisol, and vital signs.
Key facts
- Study ID
- NCT01563029
- Run by
- GlaxoSmithKline
- People needed
- 597
- Starts
- 2012-03-28
- Expected to finish
- 2014-09-24
- Last updated by the study team
- 2017-05-30
Who can join
Age: 5 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Written informed consent from at least one parent/ legal guardian to take part in the study.:
- Diagnosis of asthma
- pre-bronchodilator PEF between ≥50% to ≤90% of their best post-bronchodilator value
- Receiving therapy of short acting beta-agonist (SABA) alone, LTM, or ICS (total daily dose <FP 200mcg or equivalent)Exclusion :
You may not qualify if…
- history of life-threatening asthma
- history of asthma exacerbation for asthma within 6 months prior to screening.
- Culture-documented or suspected bacterial or viral infection
- significant abnormality or medical condition
- Present use of any tobacco products
Where it is running
- GSK Investigational Site — Costa Mesa, California, United States
- GSK Investigational Site — Huntington Beach, California, United States
- GSK Investigational Site — Long Beach, California, United States
- GSK Investigational Site — Newport Beach, California, United States
- GSK Investigational Site — Orange, California, United States
- GSK Investigational Site — Rolling Hills Estates, California, United States
- GSK Investigational Site — Aventura, Florida, United States
- GSK Investigational Site — Cocoa, Florida, United States
- GSK Investigational Site — Miami, Florida, United States
- GSK Investigational Site — Columbus, Georgia, United States
- GSK Investigational Site — Eagle, Idaho, United States
- GSK Investigational Site — Normal, Illinois, United States
- GSK Investigational Site — Shiloh, Illinois, United States
- GSK Investigational Site — Lenexa, Kansas, United States
- GSK Investigational Site — Owensboro, Kentucky, United States
- GSK Investigational Site — Stevensville, Michigan, United States
- GSK Investigational Site — Plymouth, Minnesota, United States
- GSK Investigational Site — Columbia, Missouri, United States
- GSK Investigational Site — Rolla, Missouri, United States
- GSK Investigational Site — Corning, New York, United States
- GSK Investigational Site — Raleigh, North Carolina, United States
- GSK Investigational Site — Canton, Ohio, United States
- GSK Investigational Site — Cincinnati, Ohio, United States
- GSK Investigational Site — Oklahoma City, Oklahoma, United States
- GSK Investigational Site — Little Rock, Arkansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.